N-3 polyunsaturated fatty acid regulation of hepatic gene transcription
Open accessAbstract
PURPOSE OF REVIEW: The liver plays a central role in whole body lipid metabolism and adapts rapidly to changes in dietary fat composition. This adaption involves changes in the expression of genes involved in glycolysis, de-novo lipogenesis, fatty acid elongation, desaturation and oxidation. This review brings together metabolic and molecular studies that help explain n-3 (omega-3) polyunsaturated fatty acid regulation of hepatic gene transcription. RECENT FINDINGS: Dietary n-3 polyunsaturated fatty acid regulates hepatic gene expression by targeting three major transcriptional regulatory networks: peroxisome proliferator-activated receptor alpha, sterol regulatory element binding protein-1 and the carbohydrate regulatory element binding protein/Max-like factor X heterodimer. 22:6,n-3, the most prominent n-3 polyunsaturated fatty acid in tissues, is a weak activator of peroxisome proliferator-activated receptor alpha. Hepatic metabolism of 22:6,n-3, however, generates 20:5,n-3, a strong peroxisome proliferator-activated receptor alpha activator. In contrast to peroxisome proliferator-activated receptor alpha, 22:6,n-3 is the most potent fatty acid regulator of hepatic sterol regulatory element binding protein-1. 22:6,n-3 suppresses sterol regulatory element binding protein-1 gene expression while enhancing degradation of nuclear sterol regulatory element binding protein-1 through 26S proteasome and Erk1/2-dependent mechanisms. Both n-3 and n-6 polyunsaturated fatty acid suppress carbohydrate regulatory element binding protein and Max-like factor X nuclear abundance and interfere with glucose-regulated hepatic metabolism. SUMMARY: These studies have revealed unique mechanisms by which specific polyunsaturated fatty acids control peroxisome proliferator activated receptor alpha, sterol regulatory element binding protein-1 and carbohydrate regulatory element binding protein/Max-like factor X function. As such, specific metabolic and signal transduction pathways contribute significantly to the fatty acid regulation of these transcription factors and their corresponding regulatory networks.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The TG-lowering effect of omega-3 in MASLD is attributed to their influence on master transcriptional regulators including PPARα, PPARγ, SREBP-1, and ChREBP.
“The triglyceride-lowering effect of omega-3 fatty acids in MASLD is attributed to their influence on master transcriptional regulators—including PPARα, PPARγ, SREBP-1, and ChREBP—that orchestrate fundamental hepatic lipid metabolic pathways.31,32”
Cites
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092 · see citing works
Critical nodes in signalling pathways: insights into insulin action
Taniguchi, C. M., Emanuelli, B., & Kahn, C. R. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1837 · Cited by 2,760 · see citing works
Tugwood, J. D., Issemann, I., Anderson, R. G., Bundell, K. R., McPheat, W. L., & Green, S. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05072.x · Cited by 895 · see citing works
Dentin, R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25256 · Cited by 315 · see citing works
Botolin, D., Wang, Y., Christian, B., & Jump, D. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m500365-jlr200 · Cited by 162 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Omega-3 Fatty Acids and Cardiovascular Disease
Mozaffarian, D., & Wu, J. H. Y. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.063 · Cited by 1,771 · see citing works
Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis
Rolo, A. P., Teodoro, J. S., & Palmeira, C. M. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.003 · Cited by 955 · see citing works
Very long-chain <i>n</i> -3 fatty acids and human health: fact, fiction and the future
Calder, P. C. (2018) · Proceedings of the Nutrition Society · doi:10.1017/s0029665117003950 · Cited by 419 · see citing works
Targeting inflammation in metabolic syndrome
Welty, F. K., Alfaddagh, A., & Elajami, T. K. (2016) · Translational Research · doi:10.1016/j.trsl.2015.06.017 · Cited by 287 · see citing works
de Roos, B., Mavrommatis, Y., & Brouwer, I. A. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00189.x · Cited by 151 · see citing works
Regulation of PCSK9 by nutraceuticals
Momtazi, A. A., Banach, M., Pirro, M., Katsiki, N., & Sahebkar, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.023 · Cited by 131 · see citing works
Yari, Z., Rahimlou, M., Eslamparast, T., Ebrahimi-Daryani, N., Poustchi, H., & Hekmatdoost, A. (2016) · International Journal of Food Sciences and Nutrition · doi:10.3109/09637486.2016.1161011 · Cited by 118 · see citing works
Watts, G. F., & Karpe, F. (2011) · Heart · doi:10.1136/hrt.2010.204990 · Cited by 97 · see citing works
Dietary and Pharmacological Fatty Acids and Cardiovascular Health
Wu, H., Xu, L., & Ballantyne, C. M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz174 · Cited by 59 · see citing works
Rodríguez‐Pérez, C., Ramprasath, V. R., Pu, S., Sabra, A., Quirantes‐Piné, R., Segura‐Carretero, A., & Jones, P. J. (2016) · Lipids · doi:10.1007/s11745-015-4099-4 · Cited by 16 · see citing works
Li, L., Cong, C., Zhang, X., & Zhang, X. (2026) · Diabetes, Metabolic Syndrome and Obesity · doi:10.2147/dmso.s573711
- Authors
- Jump, D. B.
- Venue
- Current Opinion in Lipidology
- Published
- 2008-06
- Volume
- 19
- Issue
- 3
- Pages
- 242-247
- ISSN
- 0957-9672 (ISSN-L)
- PMC
- PMC2764370
- OpenAlex
- W1974186154
- Cited by
- 443
- References
- 5
- Citations by year
- 2026: 13 · 2025: 5 · 2024: 9 · 2023: 14 · 2022: 6 · 2021: 24 · 2020: 26 · 2019: 20 · 2018: 18 · 2017: 31 · 2016: 32 · 2015: 30 · 2014: 32 · 2013: 29 · 2012: 40
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Current Opinion in Lipidology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 43220, R01DK043220)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- omega-3 fatty acids, hepatic gene transcription, PPARα, SREBP1, 26S proteasome, ERK signaling, glucose metabolism, hepatic lipid metabolism, dietary fat composition
- MeSH terms
- Animals, Dietary Fats, Unsaturated, Glycolysis, Humans, Liver, Transcription, Genetic, Fatty Acids, Omega-3, PPAR alpha, Lipogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review